Comparative Pharmacology
Head-to-head clinical analysis: RINVOQ versus RINVOQ LQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RINVOQ versus RINVOQ LQ.
RINVOQ vs RINVOQ LQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Janus kinase (JAK) inhibitor; selectively inhibits JAK1 and JAK2, modulating the JAK-STAT signaling pathway involved in cytokine-mediated inflammation and immune responses.
Janus kinase (JAK) inhibitor; selectively inhibits JAK1 and JAK3, modulating cytokine signaling involved in inflammation.
15 mg orally once daily, with or without food.
15 mg orally once daily; may increase to 30 mg once daily for inadequate response in certain conditions (e.g., rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis, Crohn's disease).
None Documented
None Documented
Terminal elimination half-life: 6.5–8.9 hours (mean ~7 hours) in healthy subjects; in patients with rheumatoid arthritis, similar half-life supports twice-daily dosing
Terminal half-life 3.5-7.9 hours; at steady state, effective half-life ~4.5 hours, supports twice-daily dosing.
UpToDate: 24% renal (as unchanged drug), 52% fecal (as metabolites); Clinical Pharmacology: 24% renal (unchanged), 52% fecal (metabolites), <1% biliary
Renal (24% unchanged, 20% as metabolites), biliary/fecal (48% as metabolites), total radiolabeled dose recovery ~96% over 14 days.
Category C
Category C
Janus Kinase (JAK) Inhibitor
Janus Kinase (JAK) Inhibitor